We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
-0.84%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242K
AUM Growth
-$247M
Cap. Flow
+$20M
Cap. Flow %
8,259.72%
Top 10 Hldgs %
57.4%
Holding
86
New
15
Increased
42
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$7.21M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.91M
3
VCYT icon
Veracyte
VCYT
+$5.84M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.65M
5
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$3.13M

Top Sells

Rank Stock Value
1
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.42M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.38M
3
IMGN
Immunogen Inc
IMGN
+$4.81M
4
HALO icon
Halozyme
HALO
+$2.85M
5
CYTK icon
Cytokinetics
CYTK
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$22B
$2.4K 0.99%
102,067
+1,446
+1% +$33.6K
VRDN icon
27
Viridian Therapeutics
VRDN
$2.2B
$2.33K 0.97%
126,136
+2,330
+2% +$44.8K
MCRB icon
28
Seres Therapeutics
MCRB
$46.3M
$2.33K 0.96%
16,344
+314
+2% +$48.3K
EYPT icon
29
EyePoint Inc
EYPT
$1.08B
$2.26K 0.93%
185,666
+3,780
+2% +$41.4K
VRTX icon
30
Vertex Pharmaceuticals
VRTX
$122B
$1.99K 0.82%
7,638
+2,638
+53% +$626K
NBIX icon
31
Neurocrine Biosciences
NBIX
$18.7B
$1.92K 0.79%
+20,482
New +$1.74M
CYPH
32
Cypherpunk Technologies Inc
CYPH
$66.6M
$1.81K 0.75%
103,216
+1,850
+2% +$39.6K
SNDX icon
33
Syndax Pharmaceuticals
SNDX
$1.73B
$1.76K 0.73%
101,447
+1,447
+1% +$24.4K
VRAY
34
DELISTED
ViewRay, Inc.
VRAY
$1.71K 0.71%
436,096
+8,249
+2% +$35.1K
JNCE
35
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.69K 0.7%
248,347
+2,518
+1% +$17.9K
CDXS icon
36
Codexis
CDXS
$159M
$1.67K 0.69%
+81,000
New +$1.68M
PNT
37
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.63K 0.67%
204,679
+217
+0.1% +$1.38K
FMTX
38
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$1.63K 0.67%
+174,768
New +$1.86M
ASLN
39
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.59K 0.66%
12,500
-24,955
-67% -$928K
ISEE
40
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.59K 0.66%
+94,600
New +$1.4M
SGEN
41
DELISTED
Seagen Inc. Common Stock
SGEN
$1.58K 0.65%
10,956
+108
+1% +$14.6K
ASND icon
42
Ascendis Pharma A/S
ASND
$16.5B
$1.43K 0.59%
+25,000
New +$2.9M
XENE icon
43
Xenon Pharmaceuticals
XENE
$6.2B
$1.43K 0.59%
101,081
+1,081
+1% +$32.4K
IMGN
44
CALL
DELISTED
Immunogen Inc
IMGN
$1.43K 0.59%
+300,000
New +$1.66M
BGMS
45
Bio Green Med Solution Inc
BGMS
$5.04M
$1.41K 0.58%
129
+2
+2% +$24.3K
STXS icon
46
Stereotaxis
STXS
$133M
$1.29K 0.53%
346,405
+2,169
+0.6% +$10.2K
MSAC
47
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$1.28K 0.53%
131,151
+2,569
+2% +$25K
AMYT
48
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$1.27K 0.52%
153,267
-196,946
-56% -$1.78M
PYPD icon
49
PolyPid
PYPD
$83.8M
$1.19K 0.49%
7,273
+86
+1% +$13K
LHDX
50
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$1.11K 0.46%
310,734
-204,266
-40% -$1M
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Silverarc Capital Management held 86 positions worth $242K, down 100% from $247M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Silverarc Capital Management deployed $20M of net new capital in Q1 2022, opening 15 new positions and adding to 42 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.38M trimmed.

  • Silverarc Capital Management's largest Q1 2022 buy was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.
  • Silverarc Capital Management added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $7.21M increase.
  • Silverarc Capital Management's biggest Q1 2022 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.38M.
  • Silverarc Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $5.42M.
  • Silverarc Capital Management's ten largest holdings make up 57% of its $242K portfolio in Q1 2022.
  • Silverarc Capital Management opened 15 new positions and closed 17 in Q1 2022.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $242K.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.